Core Viewpoint - The article highlights a significant rise in the stock prices of several innovative pharmaceutical companies following the announcement of the 2025 National Medical Insurance drug list, which includes a substantial number of new innovative drugs [1] Group 1: Stock Performance - WuXi AppTec (02126) saw an increase of 8.77%, trading at HKD 3.35 [1] - Kintor Pharmaceutical (02171) rose by 3.8%, reaching HKD 18.87 [1] - Beihai Kangcheng (01228) increased by 3.38%, priced at HKD 2.45 [1] - Junshi Biosciences (01877) gained 2.29%, with a share price of HKD 24.1 [1] Group 2: Drug List Adjustments - The 2025 National Medical Insurance drug list is the 8th adjustment since the establishment of the National Healthcare Security Administration [1] - A total of 114 new drugs were added to the list, including 50 Class 1 innovative drugs [1] Group 3: Notable Drug Inclusions - Fosun Pharma's (600196) Luwomei Tablets and Beihai Kangcheng's injectable Vilazodone Beta were included in the commercial insurance innovative drug list [1] - The highly anticipated CAR-T cell therapies from various companies, including Fosun Kairui's Acalabrutinib Injection and WuXi AppTec's Regorafenib Injection, were also included in the first batch of commercial insurance innovative drug list [1]

Group 1 - The core viewpoint of the article highlights a significant rise in certain innovative drug concept stocks, driven by the recent adjustment of the national medical insurance drug list in China, which includes 114 new drugs, 50 of which are classified as innovative drugs [1] - WuXi AppTec's stock (02126) increased by 8.77% to HKD 3.35, Kintor Pharmaceutical's stock (02171) rose by 3.8% to HKD 18.87, Beihai Kangcheng's stock (01228) went up by 3.38% to HKD 2.45, and Junshi Biosciences (01877) saw a 2.29% increase to HKD 24.1 [1] - Notably, Fosun Pharma's drug, Luwomei Tablets, has been included in the 2025 medical insurance directory, while Beihai Kangcheng's injectable Viraquinase β has entered the commercial insurance innovative drug directory [1] Group 2 - The article emphasizes the inclusion of several CAR-T cell therapies in the first batch of commercial insurance innovative drug directory, including Fosun Kairui's Acalabrutinib injection, WuXi AppTec's Regorafenib injection, and others from various biotech companies [1] - The adjustment of the medical insurance drug list marks the 8th update since the establishment of the National Medical Insurance Bureau, indicating ongoing efforts to enhance access to innovative treatments [1]

Core Viewpoint - Junshi Biosciences (01877) saw a morning increase of over 3%, currently up 3.23% at HKD 24.28, with a trading volume of HKD 3.177 million, following the announcement of new indications for its products being included in the National Medical Insurance Directory [1] Group 1: Product Developments - Junshi Biosciences announced that its product Toripalimab injection (brand name: Tuoyi®, product code: JS001) has received two new indications, and its product Engreitzumab injection (brand name: Junshida®, product code: JS002) has been successfully included in the National Medical Insurance Directory (2025) under the Class B category [1] - The new National Medical Insurance Directory will officially take effect on January 1, 2026 [1] Group 2: Market Position - As of the announcement date, the company has four commercialized products, including Tuoyi®, Adalimumab injection (brand name: Junmaikang®, product code: UBP1211), Dexamethasone Hydrochloride tablets (brand name: Mindewi®, product code: VV116/JT001), and Junshida®, all of which have been included in the National Medical Insurance Directory [1] - Tuoyi® is the only anti-PD-1 monoclonal antibody in the directory that is approved for the treatment of renal cancer, triple-negative breast cancer, and melanoma, with all 12 approved indications in mainland China included in the National Medical Insurance Directory [1] - Junshida® is newly included and is the only domestic PCSK9-targeted drug in the new directory for patients intolerant to statins [1]

Core Viewpoint - Junshi Biosciences (01877) has seen a stock price increase of 1.87% to 24 HKD following the announcement of new indications for its products being included in the National Medical Insurance Directory [2][5]. Group 1: Product Developments - Junshi Biosciences announced that its product Toripalimab injection (brand name: Tuoyi®, product code: JS001) has received two new indications, and its product Engreztinib injection (brand name: Junshida®, product code: JS002) has been successfully included in the National Medical Insurance Directory (2025) under the Class B category [2][5]. - The new version of the National Medical Insurance Directory will be officially implemented on January 1, 2026 [2][5]. Group 2: Product Portfolio - As of the announcement date, four commercialized products from the company, including Tuoyi®, Adalimumab injection (brand name: Junmaikang®, product code: UBP1211), Dexamethasone Hydrochloride Tablets (brand name: Mindewi®, product code: VV116/JT001), and Junshida®, have all been included in the National Medical Insurance Directory [2][5]. - Tuoyi® is the only anti-PD-1 monoclonal antibody in the directory that is approved for treating renal cancer, triple-negative breast cancer, and melanoma, with all 12 approved indications included [2][5]. - Junshida® is newly included and is the only domestic PCSK9-targeted drug in the new directory for patients intolerant to statins [2][5].

Core Viewpoint - Junshi Biosciences (01877) saw a morning increase of over 3%, currently up 3.23% at HKD 24.28, with a trading volume of HKD 3.177 million. The company announced that its products, Toripalimab injection (brand name: Tuoyi, product code: JS001) and Engreztinib injection (brand name: Junshida, product code: JS002), have been included in the National Medical Insurance Catalog (2025) under Category B, effective January 1, 2026 [1]. Group 1 - The company has successfully added two new indications for Toripalimab and has included Engreztinib in the National Medical Insurance Catalog [1]. - All 12 approved indications for Toripalimab in mainland China have been included in the National Medical Insurance Catalog, making it the only anti-PD-1 monoclonal antibody in the catalog for the treatment of renal cancer, triple-negative breast cancer, and melanoma [1]. - Engreztinib is newly included in the catalog and is the only domestic PCSK9-targeted drug for patients intolerant to statins in the new version of the catalog [1].

Group 1: National Medical Insurance Directory Inclusion - Heng Rui Medicine has multiple drugs included in the 2025 National Medical Insurance Directory [1] - Xing Qi Eye Medicine has 39 products continuing to be included in the National Medical Insurance Drug Directory [1] - Bei Da Pharmaceutical has four products included in the National Medical Insurance Drug Directory [1] - Junshi Biosciences has added indications for Tuoyi® and included Junshida® in the National Medical Insurance Directory [1] - Zhongsheng Pharmaceutical's innovative drug Angladiwei tablets have been included in the National Medical Insurance Directory through negotiation [1] - Yiling Pharmaceutical's subsidiary has its exclusive product Qifang Nasal Tablets included in the National Medical Insurance Directory, totaling 12 exclusive patented traditional Chinese medicine products [1] - Aosaikang's product Liratinib tablets (Aoyi Xin®) has been included in the 2025 National Medical Insurance Directory [1] - Kanghong Pharmaceutical's product Kangbai Xip eye injection (Langmu) has been included in the 2025 National Medical Insurance Directory [1] - Dongcheng Pharmaceutical's Technetium-99m injection has been included in the medical insurance directory; its subsidiary has received clinical trial approval for 177Lu-LNC1009 injection [1] - Micron Biomedical's Sidabena tablets have been included in the National Medical Insurance Directory for regular Class B management [1] - Haichuang Pharmaceutical's Deuteroenzalutamide soft capsules have been included in the National Medical Insurance Directory for the first time [1] - Huadong Medicine's subsidiary products and cooperative products have been included in the National Medical Insurance and commercial insurance innovative drug directory [1] - Aidi Pharmaceutical's two anti-HIV innovative drugs continue to be included in the National Medical Insurance Directory through a simplified renewal process [1] Group 2: Corporate Developments - Hengyin Technology has signed a cooperation agreement with Muxi Co., focusing on the domestic GPU scenario [1] - Jia Jian Co. is planning a change in control, with stock resuming trading on December 8 [2] - Gu Ao Technology's actual controller is planning a change in control, leading to stock suspension [2] Group 3: Financial Performance - Tianbang Food reported a commodity pig sales revenue of 654 million yuan in November, a month-on-month increase of 7.66% [3] - Tian Ci Materials' controlling shareholder has committed not to reduce company shares [3]

Capital Market Developments - The draft guidelines for the performance evaluation of fund companies have been released, with significant changes including an increase in the co-investment ratio, requiring 30% of fund company executives to invest in their own funds and 40% of fund managers to invest in their own funds. Fund managers with poor performance, defined as underperforming the benchmark by 10% over the past three years and having negative profit margins, will face a 30% salary reduction [3]. - According to a report by CITIC Securities, since the "9.24 market" last year, the overall increase in market levels has been accompanied by a systematic increase in financing scale, totaling a net increase of 1.11 trillion yuan, significantly exceeding the total scale of new public and private subjective long products since October last year [3]. - New stock subscriptions today include Chuangye Board's Nabichuan (subscription code: 301667) and the Sci-Tech Innovation Board's Youxuan Shares (subscription code: 787807) [3]. Industry Highlights - The State Administration of Foreign Exchange reported that China's gold reserves at the end of November stood at 74.12 million ounces, an increase of 30,000 ounces month-on-month, marking the 13th consecutive month of gold accumulation [8]. - The U.S. commercial space company SpaceX has seen its valuation rise to $800 billion (approximately 5.6 trillion yuan), making it the highest-valued startup globally, surpassing OpenAI, with an IPO expected next year [8]. - The Ministry of Industry and Information Technology has announced the establishment of a standardization technical committee for quantum information, highlighting quantum technology as a key focus for the 14th Five-Year Plan [8]. - The 2025 medical insurance drug list has been released, adding 114 new drugs, of which 50 are classified as innovative drugs [8]. - The China Alcoholic Drinks Circulation Association's e-commerce committee has proposed the "New Retail Anti-Internal Competition Initiative" for the liquor e-commerce sector [8]. Company-Specific Updates - Annie Co. announced that Shengshi Tianan will become the controlling shareholder, with the actual controllers changing to Li Ning and Wang Lei [10]. - Guao Technology is planning a change in control, leading to a suspension of its stock [10]. - Bohai Chemical announced plans to sell 100% of Bohai Petrochemical and acquire control of Taida New Materials, resulting in stock suspension [10]. - Morgan Stanley has raised the target price for Ping An from 70 to 85 [10]. - China Pacific Insurance's vice president Yu Ze is under investigation for serious violations of discipline and law [10]. - Double Star New Materials reported that leading companies in the BOPET industry have reached a consensus on production cuts, but the sustainability of long-term price increases remains uncertain [10]. - Guangqi Technology's subsidiary signed a contract for mass production of metamaterials worth 696 million yuan [10]. - Yitian Intelligent's wholly-owned subsidiary plans to sell 600 units of Huoqing Supercomputing's intelligent computing machines [10]. - Tianqi Materials' controlling shareholder has committed not to reduce their holdings in the company [10].

Group 1: National Medical Insurance Drug List Update - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List will be released on December 7, 2023, adding 114 new drugs, including 50 innovative Class 1 drugs [2] - The first Commercial Health Insurance Innovative Drug List will also be released on the same day, including 19 drugs, such as CAR-T and Alzheimer's treatment drugs [2] - The new drug list will officially take effect on January 1, 2026 [2] Group 2: Company Announcements - 15 A-share pharmaceutical companies announced that their products were included in the new drug list, with many innovative drug companies benefiting [2] - Zai Lab announced that its self-developed drug, Gilteritinib, was included in the National Medical Insurance Drug List, which is expected to enhance sales and market promotion [2] - Junshi Biosciences, ZhiXiang JinTai, and Elysium also had products included in the list, with Junshi's products gaining new indications and being classified under Category B of the National Medical Insurance [3] Group 3: Sales Impact - Heng Rui Medicine stated that the total sales of the newly included drugs for 2024 are estimated to be approximately 8.66 billion yuan, with 7.55 billion yuan expected for the first three quarters of 2025 [4] - The inclusion of these drugs in the National Medical Insurance Drug List is anticipated to positively impact sales, although the exact effect on operating performance is currently uncertain [4]

Group 1: Core Insights - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List was released on December 7, 2023, adding 114 new drugs, including 50 innovative drugs [1] - A new Commercial Health Insurance Innovative Drug List was also published, including 19 drugs, such as CAR-T therapies and Alzheimer's disease treatments [1] - The updated drug list will take effect on January 1, 2026 [1] Group 2: Company Announcements - On December 7, 15 A-share pharmaceutical companies announced that their products were included in the new drug list, particularly many innovative drug companies [2] - Zai Lab announced that its self-developed drug, Jikaxitinib, was included in the National Medical Insurance Drug List, which is expected to enhance sales and market accessibility [2] - Junshi Biosciences and other innovative drug companies also had products included, with Junshi's products gaining new indications in the National Medical Insurance List [2][3] Group 3: Market Impact - Heng Rui Medicine reported that the total sales of its newly included drugs are estimated to be approximately 8.66 billion yuan for 2024 and about 7.55 billion yuan for the first three quarters of 2025 [3] - The inclusion of these drugs in the National Medical Insurance List is expected to positively impact sales and long-term business development for the companies involved [2][3]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has announced the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which includes 114 new drugs and introduces the Commercial Health Insurance Innovative Drug Catalog for 2025, marking the eighth adjustment since the NHSA's establishment and the first addition of a commercial insurance catalog [1][2]. Group 1: Drug Catalog Adjustments - A total of 114 new drugs have been added to the national medical insurance catalog, including 50 Class 1 innovative drugs, while 29 drugs have been removed due to lack of clinical supply or better alternatives [2]. - The new catalog includes drugs addressing significant diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as treatments for rare diseases and chronic conditions like diabetes and autoimmune diseases [2]. - The overall success rate for the newly added innovative drugs is 88%, an increase from 76% in 2024 [2]. Group 2: Market Impact and Growth Potential - The inclusion of innovative drugs in the insurance catalog is expected to lead to rapid revenue growth for these drugs, benefiting patients and driving growth for related pharmaceutical companies [3]. - Zhongtai Securities predicts that the innovative drug market will continue to thrive, noting that the current market conditions have returned to a relatively reasonable and low position, enhancing investment safety margins and return values [3]. Group 3: Company Announcements - Green Leaf Pharmaceutical has successfully included five new products in the national medical insurance and commercial health insurance catalogs, including MiMeiXin and ZhanBiJia [4]. - Fuhong Hanlin announced that its product Fuzhining has been included in the national medical insurance catalog for 2025 [5]. - Innovent Biologics reported that seven of its innovative products have been successfully added to the new national medical insurance catalog, including the PD-1 monoclonal antibody drug [6].